HIES Clinical Trials

239 recruitingLast updated: July 25, 2026

There are 239 actively recruiting hies clinical trials across 54 countries. Studies span Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4. Top locations include Philadelphia, Pennsylvania, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


HIES Trials at a Glance

239 actively recruiting trials for hies are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Not Applicable with 53 trials, with the heaviest enrollment activity in Philadelphia, New York, and Boston. Lead sponsors running hies studies include University of Pennsylvania, Shanghai Changzheng Hospital, and Children's Hospital of Philadelphia.

Treatments under study

About HIES Clinical Trials

Looking for clinical trials for HIES? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HIES trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HIES clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 239 trials

Recruiting

SLC6A1-NDD Prospective Longitudinal Natural History Study

SLC6A1 Neurodevelopmental Disorder (NDD)Developmental and Epileptic Encephalopathies (DEE)
UCB Biopharma SRL60 enrolled3 locationsNCT07531511
Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled37 locationsNCT06916806
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

CardiomyopathiesSudden Cardiac DeathCardiac Arrest+1 more
Idoven 1903 S.L.5,342 enrolled13 locationsNCT05890716
Recruiting
Phase 2

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Cognitive DysfunctionLewy Body DiseaseAmyloid+1 more
Eli Lilly and Company350 enrolled72 locationsNCT07589595
Recruiting
Phase 2

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Duchenne Muscular DystrophyDMDNeuromuscular Diseases+2 more
Satellos Bioscience, Inc.51 enrolled21 locationsNCT07287189
Recruiting
Not Applicable

Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers

Motor Neuron DiseaseInherited NeuropathiesInherited Neuromuscular Conditions+1 more
National Institute of Neurological Disorders and Stroke (NINDS)275 enrolled1 locationNCT01900132
Recruiting
Not Applicable

Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

Peripheral Neuropathy Due to ChemotherapyPeripheral Neuropathy With Type 2 DiabetesPeripheral Neuropathies+2 more
RxFunction Inc.200 enrolled6 locationsNCT06959277
Recruiting
Phase 4

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

CardiomyopathiesArrythmia
University of Rochester100 enrolled19 locationsNCT05034432
Recruiting

Global Registry and Natural History Study for Mitochondrial Disorders

MDSNARP SyndromeLeigh Syndrome+15 more
LMU Klinikum6,000 enrolled33 locationsNCT05554835
Recruiting
Not Applicable

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

Spinal Cord Injuries (SCI)Amyotrophic Lateral Sclerosis(ALS)Muscular Dystrophies+6 more
Johns Hopkins University5 enrolled1 locationNCT07521930
Recruiting
Not Applicable

Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology

Hemopathies
Private Hospital of Confluent, France110 enrolled3 locationsNCT06713811
Recruiting
Not Applicable

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

HemoglobinopathiesImmunodeficienciesHematologic Disorders
Masonic Cancer Center, University of Minnesota30 enrolled1 locationNCT01666080
Recruiting
Phase 1

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Genetic epilepsyDevelopmental and Epileptic EncephalopathiesEpileptic Spasms+1 more
Heather Olson10 enrolled1 locationNCT06700811
Recruiting

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

IgA NephropathyDiabetic NephropathiesANCA-associated Vasculitis+4 more
Assistance Publique - Hôpitaux de Paris146 enrolled1 locationNCT07010250
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)+2 more
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

CardiomyopathiesAmyloidosisHeart Diseases+3 more
Eidos Therapeutics, a BridgeBio company587 enrolled103 locationsNCT06563895
Recruiting
Phase 1Phase 2

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

Autosomal Dominant Optic AtrophyOPA1 Gene MutationHereditary Optic Atrophies+1 more
PYC Therapeutics24 enrolled3 locationsNCT06970106